Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease

Journal of Neuroscience

Volumn 24, Issue 8, 2004, Pages 2045-2053

  Hayley, Shawn ^a,c   Crocker, Stephen J ^a,e   Smith, Patrice D ^a   Shree, Tanaya ^a   Jackson Lewis, Vernice ^b   Przedborski, Serge ^b   Mount, Matthew ^a   Slack, Ruth ^a   Anisman, Hymie ^c   Park, David S ^a,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c CARLETON UNIVERSITY   (Canada)

^d Scripps Rwesearch Institute ^*  (Canada)

^e Scripps Rwesearch Institute   (United States)

Author keywords

Cytokine; Dopamine; Fas; Kinase; Neurodegeneration; Stress

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOVIRUS VECTOR; DOPAMINE; FAS ANTIGEN; PROTEIN; PROTEIN C JUN; TRANSCRIPTION FACTOR DELTA FOSB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BASAL GANGLION; CELL ACTIVATION; CELL LOSS; CELL PROTECTION; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION; INFLAMMATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOVIRIDAE; ANIMALS; ANTIGENS, CD95; CELL DEATH; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENES, DOMINANT; GENES, REPORTER; GENETIC VECTORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; MOTOR ACTIVITY; NEURONS; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-JUN; SUBSTANTIA NIGRA;

EID: 10744223673     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4564-03.2004     Document Type: Article

References (52)

1. Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94:239-247.
2. Anglade P, Vyas S, Hirsch EC, Agid Y (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12:603-610.
3. Antolin I, Mayo JC, Sainz RM, del Brio Mde L, Herrera F, Martin V, Rodriguez C (2002) Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 943:163-173.
4. Banati RB, Daniel SE, Blunt SB (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 13:221-227.
5. Bjorklund A, Lindvall O (1975) Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res 83:531-537.
6. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172.
7. Cheramy A, Leviel V, Glowinski J (1981) Dendritic release of dopamine in the substantia nigra. Nature 289:537-542.
8. Chiueh CC, Zukowska-Grojec Z, Kirk KL, Kopin JJ (1983) 6-Fluorocatecholamine as a false adrenergic neurotransmitter. J Pharmacol Exp Ther 225:529-533.
9. Choi C, Xu X, Oh JW, Lee SJ, Gillespie GY, Park H, Jo H, Benveniste EN (2001) Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res 61:3084-3091.
10. Choi C, Gillespie GY, Van Wagoner NJ, Benveniste EN (2002) Fas engagement increases expression of interleukin-6 in human glioma cells. J Neurooncol 56:13-19.
11. Choi-Lundberg DL, Lin Q, Schallert T, Crippens D, Davidson BL, Chang YN, Chiang YL, Qian J, Bardwaj L, Bohn MC (1998) Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 154:261-275.
12. Crocker SJ, Lamba WR, Smith PD, Callaghan SM, Slack RS, Anisman H, Park DS (2001) c-Jun mediates axotomy-induced dopamine neuron death in vivo. Proc Natl Acad Sci USA 98:13385-13390.
13. Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, Grimm E, Callaghan SM, Slack RS, Melloni E, Przedborski S, Robertson GS, Anisman H, Merali Z, Park DS (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 23:4081-4091.
14. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano G (2002) Immune processes in the pathogenesis of Parkinson's disease: a potential role for microglia and nitric oxide. Med Sci Monit 8:RA165-RA177.
15. Dittel BN, Merchant RM, Janeway Jr CA (1999) Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 162:6392-6400.
16. Dragunow M, Butterworth N, Waldvogel H, Faull RL, Nicholson LF (1995) Prolonged expression of Fos-related antigens, Jun B and TrkB in dopamine-denervated striatal neurons. Brain Res Mol Brain Res 30:393-396.
17. Eberhardt O, Schulz JB (2003) Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol Lett 139:135-151.
18. Ferrer I, Puig B, Krupinsk J, Carmona M, Blanco R (2001) Fas and Fas ligand expression in Alzheimer's disease. Acta Neuropathol (Berl) 102:121-131.
19. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. New York: Academic.
20. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE (1999) Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97.
21. Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt-Prigent A, Ruberg M, Agid Y, Hirsch EC (2001) Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21:2247-2255.
22. Hartmann A, Mouatt-Prigent A, Faucheux BA, Agid Y, Hirsch EC (2002) FADD: a link between TNF family receptors and caspases in Parkinson's disease. Neurology 58:308-310.
23. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451-1453.
24. Herdegen T, Claret FX, Kallunki T, Martin-Villalba A, Winter C, Hunter T, Karin M (1998) Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J Neurosci 18:5124-5135.
25. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
26. Hohlbaum AM, Gregory MS, Ju ST, Marshak-Rothstein A (2001) Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 167:6217-6224.
27. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269.
28. Jellinger KA (2002) Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl 62:347-376.
29. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
30. Lasham A, Lindridge E, Rudert F, Onrust R, Watson J (2000) Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 252:1-13.
31. Lee H, Ferguson TA (2003) Biology of FasL. Cytokine Growth Factor Rev 14:325-335.
32. Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J, Schenkel J, Herdegen T, Debatin KM (1999) CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19:3809-3817.
33. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T (1998) Caspase 1-independent IL-1 beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 4:1287-1292.
34. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, Nagatsu T (1996) The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 220:195-198.
35. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, Davis RJ, Shirasaki Y, Greenberg ME (2001) β-Amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21:7551-7560.
36. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 60:277-290.
37. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36:2503-2508.
38. Nicotra A, Parvez S (2002) Apoptotic molecules and MPTP-induced cell death. Neurotoxicol Teratol 24:599-605.
39. Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA, Liles WC (2003) Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol 70:6209-6216.
40. Petitto JM, Huang Z, Lo J, Beck RD, Rinker C, Hartemink DA (2002) Relationship between the development of autoimmunity and sensorimotor gating in MRL-lpr mice with reduced IL-2 production. Neurosci Lett 328:304-308.
41. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93:4565-4571.
42. Sabelko-Downes KA, Russell JH, Cross AH (1999) Role of Fas-FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease. J Neuroimmunol 100:42-52.
43. Sakic B, Szechtman H, Keffer M, Talangbayan H, Stead R, Denburg JA (1992) A behavioral profile of autoimmune lupus-prone MRL mice. Brain Behav Immun 6:265-285.
44. Seegal RF, Brosch KO, Bush B (1986) High-performance liquid chromatography of biogenic amines and metabolites in brain, cerebrospinal fluid, urine and plasma. J Chromatogr 377:131-144.
45. Soltys Z, Ziaja M, Pawlinski R, Setkowicz Z, Janeczko K (2001) Morphology of reactive microglia in the injured cerebral cortex. Fractal analysis and complementary quantitative methods. J Neurosci Res 63:90-97.
46. Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048.
47. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW (1998) A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 44:S142-S148.
48. Trimmer PA, Smith TS, Jung AB, Bennett Jr JP (1996) Dopamine neurons from transgenic mice with a knock-out of the p53 gene resist MPTP neurotoxicity. Neurodegeneration 5:233-239.
49. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci USA 98:2837-2842.
50. Wallach D, Boldin M, Goncharov T, Goltsev Y, Mett I, Malinin N, Adar R, Kovalenko A, Varfolomeev E (1996) Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. Behring Inst Mitt 97:144-155.
51. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, Schulz JB (2001) Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98:10433-10438.
52. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13:290-296.